Robert Wolf, PharmD
Assistant Professor, Department of Hematology & Oncology Pharmacy, Mayo Clinic, Rochester, MNAuthored Items
April 9, 2018 | Rx Profiler – Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
Breast cancer is the most common cancer in women and remains a leading cause of cancer-related morbidity, mortality, and resource utilization. For patients with advanced breast cancer, prognosis remains especially suboptimal, primarily because of acquired pharmacologic resistance.
Last modified: June 25, 2018